Anti-angiogenic ophthalmic agents
What are Anti-angiogenic ophthalmic agents?
Anti-angiogenic ophthalmic agents act as vascular endothelial growth factor (VEGF) antagonists. When retinal pigment cells become ischemic and dry up VEGF stimulates generation of new blood vessels by a process called neovascularization. During the generation of new blood vessels in the retina, if the blood vessels do not generate properly it causes leaking. This can lead to loss of vision.
Anti-angiogenic ophthalmic agents are used to stop neovascularization in age related macular degeneration.
List of Anti-angiogenic ophthalmic agents:
|Drug Name||Reviews||Avg. Ratings|
|brolucizumab systemic (Pro)||0 reviews||10|
|pegaptanib ophthalmic (Pro)||1 review||9.0|
|ranibizumab ophthalmic (Pro)||14 reviews||6.9|
|aflibercept ophthalmic (Pro)||29 reviews||6.5|
|For ratings, users were asked how effective they found the medicine while considering positive/adverse effects and ease of use (1 = not effective, 10 = most effective).|
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.